MedTrace Logo

Jowl Improvement With Injectable Fillers

NCT04389866 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-02-15

Study results available
· View outcomes & findings →

Summary

This is a prospective clinical study to demonstrate a reduction in jowling and laxity of the jawline that can be achieved following facial volume enhancement using JUVÉDERM VOLUMA™ XC (0.3% w/w lidocaine). The secondary measure will be if this can be achieved with Jawline injection only, or if a superior result can be obtained with both cheek and jowl injection.

Conditions

  • Jowls

Interventions

DEVICE

JUVÉDERM VOLUMA™ XC

Injectable gel

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Advanced Dermatology

    lead OTHER

Principal Investigators

  • Amy Taub, MD · Advanced Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-25
Primary Completion
2022-10-05
Completion
2022-10-05
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389866 on ClinicalTrials.gov